[1] Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet. 2022;399(10333):1412–28.
[2] Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. JNCI J Natl Cancer Inst. 2018;110(4):354–61.
[3] Santoro A, Angelico G, Travaglino A, Inzani F, Arciuolo D, Valente M, et al. New pathological and clinical insights in endometrial cancer in view of the updated ESGO/ESTRO/ESP guidelines. Cancers. 2021;13(11):2623.
[4] Duncan BW, Murphy KE, Maness PF. Molecular mechanisms of L1 and NCAM adhesion molecules in synaptic pruning, plasticity, and stabilization. Front Cell Dev Biol. 2021;9:625340.
[5] Stoyanova II, Lutz D. Functional diversity of neuronal cell adhesion and recognition molecule L1CAM through proteolytic cleavage. Cells. 2022;11(19):3085.
[6] Sytnyk V, Leshchyns’ka I, Schachner M. Neural cell adhesion molecules of the immunoglobulin superfamily regulate synapse formation, maintenance, and function. Trends Neurosci. 2017;40(5):295–308.
[7] Kim J, Kim SI, Kim NR, Kim H, Kim HS, Chung HH, et al. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer. Gynecol Oncol. 2023;174:231–8.
[8] Giannini A, D’Oria O, Corrado G, Bruno V, Sperduti I, Bogani G, et al. The role of L1CAM as predictor of poor prognosis in stage I endometrial cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2024;309(3):789–99.
[9] Kommoss F, Kommoss F, Grevenkamp F, Bunz AK, Taran FA, Fend F, et al. L1CAM: amending the “low-risk” category in endometrial carcinoma. J Cancer Res Clin Oncol. 2017;143:255–62.
[10] Hoang LN, Kinloch MA, Leo JM, Grondin K, Lee CH, Ewanowich C, et al. Interobserver agreement in endometrial carcinoma histotype diagnosis varies depending on The Cancer Genome Atlas (TCGA)-based molecular subgroup. Am J Surg Pathol. 2017;41(2):245–52.
[11] Arciuolo D, Travaglino A, Santoro A, Scaglione G, D’Alessandris N, Valente M, et al. L1CAM expression in Microcystic, Elongated, and fragmented (MELF) glands predicts Lymph Node involvement in endometrial Carcinoma. Cancers. 2022;14(15):3635.
[12] Duraiyan J, Govindarajan R, Kaliyappan K, Palanisamy M. Applications of immunohistochemistry. J Pharm Bioallied Sci [Internet]. 2012 Aug [cited 2024 Aug 29];4(Suppl 2):S307. Available from: https://journals.lww.com/jpbs/fulltext/2012/04002/applications_of_immunohistochemistry.47.aspx
[13] Dabbs DJ. Diagnostic immunohistochemistry: theranostic and genomic applications. Elsevier Health Sciences; 2010.
[14] Angiolini F, Cavallaro U. The pleiotropic role of L1CAM in tumor vasculature. Int J Mol Sci. 2017;18(2):254.
[15] Wu Z, Wu Y, Liu Z, Song Y, Ge L, Du T, et al. L1CAM deployed perivascular tumor niche promotes vessel wall invasion of tumor thrombus and metastasis of renal cell carcinoma. Cell Death Discov. 2023;9(1):112.
[16] Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Abdel Azim S, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst. 2013;105(15):1142–50.
[17] Notaro S, Reimer D, Duggan-Peer M, Fiegl H, Wiedermair A, Rössler J, et al. Evaluating L1CAM expression in human endometrial cancer using qRT-PCR. Oncotarget. 2016;7(26):40221.
[18] Dellinger TH, Smith DD, Ouyang C, Warden CD, Williams JC, Han ES. L1CAM is an independent predictor of poor survival in endometrial cancer—an analysis of The Cancer Genome Atlas (TCGA). Gynecol Oncol. 2016;141(2):336–40.
[19] Van Gool IC, Stelloo E, Nout RA, Nijman HW, Edmondson RJ, Church DN, et al. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Mod Pathol. 2016;29(2):174–81.
[20] Van Der Putten LJ, Visser N, Van de Vijver K, Santacana M, Bronsert P, Bulten J, et al. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br J Cancer. 2016;115(6):716–24.
[21] Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, et al. L1CAM as a prognostic marker in stage I endometrial cancer: a validation study. BMC Cancer. 2016;16:1–8.
[22] Geels YP, Pijnenborg JM, Gordon BB, Fogel M, Altevogt P, Masadah R, et al. L1CAM expression is related to non-endometrioid histology, and prognostic for poor outcome in endometrioid endometrial carcinoma. Pathol Oncol Res. 2016;22:863–8.
[23] Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Pathol Clin Res. 2017;3(4):279–93.
[24] Tangen IL, Kopperud RK, Visser N, Staff AC, Tingulstad S, Marcickiewicz J, et al. Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. Br J Cancer. 2017;117(6):840–7.
[25] Kommoss S, Hartkopf AD, Krämer B, Bunz AK, Grevenkamp F, Kommoss F, et al. Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma. J Cancer Res Clin Oncol. 2017;143:2183–8.
[26] Soovares P, Pasanen A, Bützow R, Lassus H. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma. Gynecol Oncol. 2017;146(3):615–22.
[27] Azim SA, Sprung S, Mutz-Dehbalaie I, Fessler S, Zeimet AG, Marth C. L1CAM and HER2 expression in early endometrioid uterine cancer. Int J Gynecol Pathol. 2017;36(4):356–63.
[28] Pasanen A, Loukovaara M, Tuomi T, Butzow R. Preoperative risk stratification of endometrial carcinoma: L1CAM as a biomarker. Int J Gynecol Cancer. 2017;27(7):1318–24.
[29] Versluis M, Plat A, de Bruyn M, Matias-Guiu X, Trovic J, Krakstad C, et al. L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial–mesenchymal transition. Virchows Arch. 2018;473:591–8.
[30] Van Der Putten LJ, Visser NC, Van de Vijver K, Santacana M, Bronsert P, Bulten J, et al. Added Value of Estrogen Receptor, ProgesteroneReceptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. Int J Gynecol Cancer. 2018;28(3):514–23.
[31] Geels YP, van der Putten LJ, van Tilborg AA, Nienhaus BE, van den Berg-van SH, Snijders MP, et al. Immunohistochemical profiles of endometrioid endometrial carcinomas with and without metastatic disease. Appl Immunohistochem Mol Morphol. 2018;26(3):173–9.
[32] Salem AM, Mahdy ER. Sex-determining region y (SRY)-Box2 (SOX2) & L1-cell adhesion molecule (L1CAM) expressions in endometrioid carcinoma of the uterus; An Immunohistochemical Study. Ann Cytol Pathol. 2018;2(1):001–8.
[33] de Freitas D, Aguiar FN, Anton C, Bacchi CE, Carvalho JP, Carvalho FM. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion. PLoS One. 2018;13(12):e0209294.
[34] Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, et al. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer. 2018;119(4):480–6.
[35] Corrado G, Laquintana V, Loria R, Carosi M, de Salvo L, Sperduti I, et al. Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers. J Exp Clin Cancer Res. 2018;37:1–10.
[36] Vizza E, Mancini E, Laquintana V, Loria R, Carosi M, Baiocco E, et al. The prognostic significance of positive peritoneal cytology in endometrial cancer and its correlations with L1-CAM biomarker. Surg Oncol. 2019;28:151–7.
[37] Asano H, Hatanaka KC, Matsuoka R, Dong P, Mitamura T, Konno Y, et al. L1CAM predicts adverse outcomes in patients with endometrial cancer undergoing full lymphadenectomy and adjuvant chemotherapy. Ann Surg Oncol. 2020;27:2159–68.
[38] Elyamany G, Shams Eldin M, Abd Elhamid A, El-Sayed M. Prognostic significance of L1 cell adhesion molecule (L1CAM) expression in endometrial carcinoma. J Egypt Natl Canc Inst. 2020;32(1):38.
[39] Chalia J, Hussein M, Farooqui M, Mattson J, Mullany SA, Klein ME, et al. Concurrent immunohistochemical testing of L1CAM and MMR proteins adds value in risk stratification of endometrial cancer: a proof of concept. Eur J Gynaecol Oncol. 2021;42(5).
[40] Guo M, Gong H, Nie D, Li Z. High L1CAM expression predicts poor prognosis of patients with endometrial cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2021;100(13):e25330.
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications